You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
At an AMP virtual meeting workshop, a Mayo Clinic lab director offered advice on what diseases to include, how to handle VUSs, and other considerations for ECS.
The company performed 84,067 total tests in Q3 but missed the analysts' average estimates on the top and bottom lines.
The investment bank projects medium-term revenue growth in the low teens, thanks to new test launches and expanded payor contracts for the company.
Asuragen will develop assays for PacBio's long-read next-generation sequencing systems, with an initial focus on developing a carrier screening assay.
The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.
Breast cancer risk in carriers of pathogenic CHEK2 variants may be classified as low, moderate, or high by adding in polygenic risk score and family history data.
The firm plans to use the cash to support commercial expansion of its NIPT to all US states and fund R&D for future diagnostic tests, including liquid biopsies.
Researchers in Australia are beginning a trial to offer parents-to-be free genetic testing for about 700 conditions, according to the Sydney Morning Herald.
The government-backed project aims to better understand genetic diversity around the South Asian country while helping to inform clinical applications.
The company processed more than 200,000 tests during the quarter, an increase of 20 percent compared to the 167,000 tests it processed in Q3 of last year.
Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.
Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.
Science reports that a Dutch research funding agency is combating a ransomware attack.
In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.